Zacks: Brokerages Expect TAIWAN LIPOSOME/S (TLC) to Post -$0.20 Earnings Per Share

Zacks: Brokerages Expect TAIWAN LIPOSOME/S (TLC) to Post -$0.20 Earnings Per Share

Wall Street brokerages forecast that TAIWAN LIPOSOME/S (NASDAQ:TLC) will announce earnings of ($0.20) per share for the current quarter, according to Zacks. Two analysts have provided estimates for TAIWAN LIPOSOME/S’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.26). TAIWAN LIPOSOME/S reported earnings per share of ($0.14) during the same quarter last year, which suggests a negative year-over-year growth rate of 42.9%. The company is expected to report its next earnings results on Thursday, August 8th.

On average, analysts expect that TAIWAN LIPOSOME/S will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($1.16) to ($0.46). For the next year, analysts expect that the firm will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.28) to ($0.76). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for TAIWAN LIPOSOME/S.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. TAIWAN LIPOSOME/S had a negative return on equity of 150.37% and a negative net margin of 414.31%. The company had revenue of $5.11 million for the quarter, compared to analyst estimates of $3.00 million.

Several brokerages have recently weighed in on TLC. Zacks Investment Research lowered TAIWAN LIPOSOME/S from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating on shares of TAIWAN LIPOSOME/S in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald set a $11.00 target price on TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a research report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.33.

Hedge funds and other institutional investors have recently modified their holdings of the company. Karst Peak Capital Ltd acquired a new stake in shares of TAIWAN LIPOSOME/S during the 4th quarter worth about $3,129,000. Millennium Management LLC acquired a new stake in shares of TAIWAN LIPOSOME/S during the 4th quarter worth about $602,000. Finally, Morgan Stanley raised its position in shares of TAIWAN LIPOSOME/S by 257,350.0% during the 1st quarter. Morgan Stanley now owns 257,450 shares of the company’s stock worth $1,502,000 after acquiring an additional 257,350 shares in the last quarter. 2.17% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ TLC traded up $0.02 during midday trading on Friday, hitting $5.33. 300 shares of the company’s stock were exchanged, compared to its average volume of 6,079. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.45 and a current ratio of 3.45. TAIWAN LIPOSOME/S has a twelve month low of $5.02 and a twelve month high of $11.00. The firm has a market capitalization of $183.95 million and a PE ratio of -11.66.

TAIWAN LIPOSOME/S Company Profile

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Story: Investing in Growth Stocks

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment

Zacks: Brokerages Await TAIWAN LIPOSOME/S (TLC) to Post -$0.20 Receiveds Per Share

Zacks: Brokerages Await TAIWAN LIPOSOME/S (TLC) to Post -$0.20 Receiveds Per Share

Wall Street brokerages forecast that TAIWAN LIPOSOME/S (NASDAQ:TLC) will announce earnings of ($0.20) per share for the current quarter, according to Zacks. Two analysts have provided estimates for TAIWAN LIPOSOME/S’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.26). TAIWAN LIPOSOME/S reported earnings per share of ($0.14) during the same quarter last year, which suggests a negative year-over-year growth rate of 42.9%. The company is expected to report its next earnings results on Thursday, August 8th.

On average, analysts expect that TAIWAN LIPOSOME/S will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($1.16) to ($0.46). For the next year, analysts expect that the firm will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.28) to ($0.76). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for TAIWAN LIPOSOME/S.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. TAIWAN LIPOSOME/S had a negative return on equity of 150.37% and a negative net margin of 414.31%. The company had revenue of $5.11 million for the quarter, compared to analyst estimates of $3.00 million.

Several brokerages have recently weighed in on TLC. Zacks Investment Research lowered TAIWAN LIPOSOME/S from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating on shares of TAIWAN LIPOSOME/S in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald set a $11.00 target price on TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a research report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.33.

Hedge funds and other institutional investors have recently modified their holdings of the company. Karst Peak Capital Ltd acquired a new stake in shares of TAIWAN LIPOSOME/S during the 4th quarter worth about $3,129,000. Millennium Management LLC acquired a new stake in shares of TAIWAN LIPOSOME/S during the 4th quarter worth about $602,000. Finally, Morgan Stanley raised its position in shares of TAIWAN LIPOSOME/S by 257,350.0% during the 1st quarter. Morgan Stanley now owns 257,450 shares of the company’s stock worth $1,502,000 after acquiring an additional 257,350 shares in the last quarter. 2.17% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ TLC traded up $0.02 during midday trading on Friday, hitting $5.33. 300 shares of the company’s stock were exchanged, compared to its average volume of 6,079. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.45 and a current ratio of 3.45. TAIWAN LIPOSOME/S has a twelve month low of $5.02 and a twelve month high of $11.00. The firm has a market capitalization of $183.95 million and a PE ratio of -11.66.

TAIWAN LIPOSOME/S Company Profile

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Story: Investing in Growth Stocks

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment

Zacks: Brokerages Await TAIWAN LIPOSOME/S (TLC) to Post -$0.20 Revenue Per Share

Zacks: Brokerages Await TAIWAN LIPOSOME/S (TLC) to Post -$0.20 Revenue Per Share

Wall Street brokerages forecast that TAIWAN LIPOSOME/S (NASDAQ:TLC) will announce earnings of ($0.20) per share for the current quarter, according to Zacks. Two analysts have provided estimates for TAIWAN LIPOSOME/S’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.26). TAIWAN LIPOSOME/S reported earnings per share of ($0.14) during the same quarter last year, which suggests a negative year-over-year growth rate of 42.9%. The company is expected to report its next earnings results on Thursday, August 8th.

On average, analysts expect that TAIWAN LIPOSOME/S will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($1.16) to ($0.46). For the next year, analysts expect that the firm will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.28) to ($0.76). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for TAIWAN LIPOSOME/S.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. TAIWAN LIPOSOME/S had a negative return on equity of 150.37% and a negative net margin of 414.31%. The company had revenue of $5.11 million for the quarter, compared to analyst estimates of $3.00 million.

Several brokerages have recently weighed in on TLC. Zacks Investment Research lowered TAIWAN LIPOSOME/S from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating on shares of TAIWAN LIPOSOME/S in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald set a $11.00 target price on TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a research report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.33.

Hedge funds and other institutional investors have recently modified their holdings of the company. Karst Peak Capital Ltd acquired a new stake in shares of TAIWAN LIPOSOME/S during the 4th quarter worth about $3,129,000. Millennium Management LLC acquired a new stake in shares of TAIWAN LIPOSOME/S during the 4th quarter worth about $602,000. Finally, Morgan Stanley raised its position in shares of TAIWAN LIPOSOME/S by 257,350.0% during the 1st quarter. Morgan Stanley now owns 257,450 shares of the company’s stock worth $1,502,000 after acquiring an additional 257,350 shares in the last quarter. 2.17% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ TLC traded up $0.02 during midday trading on Friday, hitting $5.33. 300 shares of the company’s stock were exchanged, compared to its average volume of 6,079. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.45 and a current ratio of 3.45. TAIWAN LIPOSOME/S has a twelve month low of $5.02 and a twelve month high of $11.00. The firm has a market capitalization of $183.95 million and a PE ratio of -11.66.

TAIWAN LIPOSOME/S Company Profile

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Story: Investing in Growth Stocks

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment